Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration‐resistant prostate cancer

Published:2019-09-09 Issue:15 Volume:79 Page:1752-1761
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

George Daniel J.¹²,Halabi Susan¹³,Healy Patrick¹³,Barak Ian¹³,Winters Carolyn¹,Anand Monika¹^ORCID,Wilder Rhonda¹,Klein Melissa¹,Martinez Elia⁴,Nixon Andrew B.¹²,Harrison Michael R.¹²,Szmulewitz Russell⁴,Armstrong Andrew J.¹²

Affiliation:

1. Duke Cancer Institute Center for Prostate and Urologic Cancers Duke University Durham North Carolina

2. Division of Medical Oncology, Department of Medicine Duke University Durham North Carolina

3. Department of Biostatistics Duke University Durham North Carolina

4. Department of Medicine, Section of Hematology/Oncology University of Chicago Chicago Illinois

Funder

U.S. Department of Defense

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23899

Reference49 articles.

1. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

2. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

3. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The multifaceted functions of DNA‐PKcs: implications for the therapy of human diseases;MedComm;2024-06-19

2. Therapeutic Drug Monitoring of Pazopanib in Renal Cell Carcinoma and Soft Tissue Sarcoma: A Systematic Review;Therapeutic Drug Monitoring;2024-04-30

3. Programmed cell death, redox imbalance, and cancer therapeutics;Apoptosis;2021-07-08